<DOC>
	<DOCNO>NCT00428064</DOCNO>
	<brief_summary>To assess equivalence rate functional graft survival 12 month transplantation patient receive continuous therapy cyclosporine ( CsA , Sandimmune , Neoral ) sirolimus versus induction CsA sirolimus follow CsA elimination concentration-controlled sirolimus .</brief_summary>
	<brief_title>Study Evaluating Sirolimus Cyclosporine Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Endstage renal disease , patient receive primary secondary renal allograft cadaveric donor , livingunrelated donor , livingrelated ( exclude 0 antigen mismatch ) donor . Women childbearing potential must negative pregnancy test sirolimus administration agree use medically acceptable method contraception throughout treatment period 3 month follow discontinuation sirolimus Evidence active systemic localize major infection time initial sirolimus administration Evidence infiltrate , cavitation , consolidation chest xray obtain prestudy screening . Chronic antiarrhythmic therapy ventricular arrhythmia cardiac abnormality contraindicate general anesthesia surgery</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Renal allograft</keyword>
	<keyword>Renal</keyword>
	<keyword>Kidney</keyword>
	<keyword>Transplant</keyword>
</DOC>